Rynki

Twoje finanse

Biznes

Forum

SOPHARMA AD: Standalone interim financial statements of Sopharma AD for Q3 2025

Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:
  1. SFA_Q3_2025_ind_financial_statements.rar

przewiń, aby zobaczyć całą tabelę

POLISH FINANCIAL SUPERVISION AUTHORITY

reklama

UNI - EN REPORT No

212

/

2025

Date of issue:

2025-10-30

Short name of the issuer

SOPHARMA AD

Subject

Standalone interim financial statements of Sopharma AD for Q3 2025

Official market - legal basis

Art. 56. 1. 2 of Act on Public Offering

Unofficial market - legal basis

Contents of the report:

Standalone interim financial statements of Sopharma AD for Q3 2025

Annexes

File

Description

SFA_Q3_2025_ind_financial_statements.rar

Standalone interim financial statements of Sopharma AD for Q3 2025

przewiń, aby zobaczyć całą tabelę

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD

Farmaceutyczny (far)

(short name of the issuer)

(sector according to clasification

of the WSE in Warsow)

1220

Sofia

(post code)

(city)

IlienskoShosse

16

(street)

(number)

+359 2 813 42 00

+359 2 936 02 86

(phone number)

(fax)

(e-mail)

(web site)

nd

(NIP)

(REGON)

przewiń, aby zobaczyć całą tabelę

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date

Name

Position / Function

Signature

2025-10-30

Ognian Ivanov Donev

Executive Director

Źródło: Komunikaty spółek (ESPI)
powiązane
polecane
najnowsze
popularne
najnowsze
bankier na skróty